StockMarketWire.com - Creo Medical said it had entered into the second phase of a clinical education programme in the US for its endoscopic minimally-invasive surgical devices.

The second phase involved three additional US clinicians being trained at a major US hospital, which was one of the first to place commercial orders for the company's so-called Speedboat device.

'Creo's clinical education programme ensures that first adopters of Speedboat, having been carefully mentored, can deliver training in this emerging field of surgical endoscopy to their fellow clinicians at a consistently high standard, safeguarding quality control and ensuring best patient outcomes,' it said.

'This new phase of the programme will see Creo establish the first in a series of US training centres run by US key opinion leaders who have already adopted Speedboat.'


At 2:44pm: [LON:CREO] Creo Medical Group Plc share price was +0.5p at 133.5p



Story provided by StockMarketWire.com